Our Pricing Policy Gives You Flexibility and Cost-effectiveness

Our information is prepared by highly skilled, experienced professionals who are experts in generic pharmaceuticals.  Because we benefit from economies of scale, we believe that there is no way of obtaining the same quality of information contained in our reports at a lower economic cost.

Value-based Pricing Model

Report pricing considers the benefits obtained by customers; price levels for a drug report are allocated according to complexity of the patent environment, the degree of difficulty in compiling the report, and the time to patent expiry in major territories.

Per-drug Pricing

Paying per-drug avoids wasting money on accessing whole databases where many components are largely irrelevant, and allows fairer pricing of reports for drugs that exist in relatively simpler patent landscapes.

Access Level Pricing

Our two-stage reporting levels (Pipeline Selector then Pipeline Developer) allow cost-effective management by only paying for the depth of information required to make the necessary decision.

Patent Searching Is Costly
We are aware that patent information is available in the public domain, and can be identified from limited sources.  We ask you to consider the following when deciding whether to attempt to source this information in-house:

·         Costs of diverting non-information professionals from their core competencies to research patent information

·         Expense of subscribing to and searching professional databases necessary to conduct a comprehensive search

·         Cost to your organisation in terms of wasted development costs, time, legal proceedings and lost business opportunities if you do not   use professional services and fail to identify critical information.